Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir

Hsin Wei Fang, Yi Hao Yen, Chao Hung Hung, Jing Houng Wang, Tsung Hui Hu, Sheng Nan Lu, Chien Hung Chen*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

1 Scopus citations

Abstract

Background: The predictors of persistent virological suppression after clinical relapse remain unclear. Aims: To investigate the predictors of retreatment or persistent virological suppression after clinical relapse in chronic hepatitis B (CHB) patients who discontinued entecavir or tenofovir disoproxil fumarate (TDF). Methods: A total of 243 hepatitis B e antigen-negative CHB patients without cirrhosis who experienced clinical relapse after entecavir or TDF cessation were enrolled. Results: Of the 243 CHB patients, 192 received retreatment and 51 did not receive retreatment after clinical relapse. Of the 51 patients without retreatment, 23 achieved persistent virological suppression (persistent HBV DNA < 2000 IU/mL at least 2 years) and 10 experienced hepatitis B surface antigen (HBsAg) loss. The Cox regression analysis showed that short consolidation duration, short duration of the first clinical relapse from the end of treatment (EOT), and high bilirubin and HBV DNA levels at the first clinical relapse were independent predictors of retreatment. Long duration of the first clinical relapse from the EOT and low HBsAg levels at the first clinical relapse were independent factors of patients with persistent virological suppression. The rates of persistent virological suppression at the first clinical relapse among patients with HBsAg < 100 and ≥ 100 IU/mL were 44.4% (12/27) and 5.1% (11/216) (P < 0.001), respectively. Baseline HBsAg levels and no retreatment requirement were independent factors associated with HBsAg loss. Conclusions: The HBsAg of 100 IU/mL at the first clinical relapse could predict persistent virological suppression after clinical relapse in patients who discontinued entecavir or TDF therapy.

Original languageEnglish
Pages (from-to)3402-3411
Number of pages10
JournalDigestive Diseases and Sciences
Volume67
Issue number7
DOIs
StatePublished - 07 2022

Bibliographical note

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Keywords

  • Clinical relapse
  • Entecavir
  • Hepatitis B surface antigen
  • Hepatitis B virus
  • Tenofovir

Fingerprint

Dive into the research topics of 'Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir'. Together they form a unique fingerprint.

Cite this